Lercanidipina Gp (Lercanidipine Hydrochloride)

Lercanidipine is a dihydropyridine calcium channel blocker used primarily in the treatment of hypertension.

• Hypertension: lowers elevated blood pressure in adults with primary hypertension.
• Essential hypertension: provides sustained blood pressure control in patients with essential hypertension.
• Isolated systolic hypertension: helps reduce systolic pressure in patients with isolated systolic hypertension.

• Lercanidipine selectively blocks L-type calcium channels on vascular smooth‑muscle cells, reducing calcium influx. This inhibition leads to relaxation of arterial smooth muscle, vasodilation, and a decrease in peripheral vascular resistance, which together lower systolic and diastolic blood pressure.

Lercanidipine may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Headache: mild to moderate headache occurring shortly after dose initiation.
• Flushing: sensation of warmth and redness, especially on the face and neck.
• Peripheral edema: swelling of the ankles or lower legs due to fluid accumulation.
• Dizziness: light‑headed feeling, often related to blood pressure changes.
• Fatigue: general tiredness without a clear cause.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat that may compromise breathing.
• Severe hypotension: marked drop in blood pressure leading to fainting or shock.
• Myocardial infarction: rare occurrence of heart attack, particularly in patients with pre‑existing coronary disease.
• Hepatic dysfunction: abnormal liver enzyme elevations indicating possible liver injury.
• Allergic reactions: rash, pruritus, or anaphylaxis requiring immediate medical attention.

Before initiating therapy with Lercanidipine, several safety considerations should be observed.

• Blood pressure monitoring: measure baseline and periodic blood pressure to assess efficacy and avoid excessive drops.
• Renal impairment: use cautiously in patients with severe renal dysfunction; adjust monitoring frequency.
• Hepatic impairment: consider dose adjustment or close observation in moderate to severe liver disease.
• Concomitant antihypertensives: avoid excessive hypotension when combined with other blood‑pressure‑lowering agents.
• Pregnancy and lactation: safety not established; avoid unless clearly indicated.
• Store at room temperature: keep in the original container, protect from moisture and light.

Lercanidipine can interact with several drug classes, influencing its safety and effectiveness.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations and precipitate hypotension.
• Grapefruit juice: can raise drug levels, enhancing the risk of adverse effects.
• Other calcium channel blockers: additive vasodilatory effect may cause severe hypotension.

Moderate Interactions (Monitor Closely)

• Diuretics: may potentiate antihypertensive effect; monitor blood pressure and electrolytes.
• Beta‑blockers: combined effect on heart rate; watch for bradycardia.
• ACE inhibitors or ARBs: additive blood‑pressure reduction; adjust therapy as needed.